echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > Cell: Gao Fu's team developed a new generation of recombinant protein vaccines to effectively prevent Omicron

    Cell: Gao Fu's team developed a new generation of recombinant protein vaccines to effectively prevent Omicron

    • Last Update: 2022-06-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Written | Edited by Lowis Liu | Typesetting by Wang Duoyu | Shui Chengwen On April 26, 2022, Gao Fu, Academician of Beijing Institutes of Biological Sciences, Chinese Academy of Sciences, Professor Wang Peiyi, Director of the Cryo-EM Center of Southern University of Science and Technology, Researcher Dai Lianpan, Institute of Microbiology, Chinese Academy of Sciences, Chinese Academy of Medical Sciences Researcher Peng Xiaozhong of the Institute of Biology, Chief Biosafety Expert of the Chinese Center for Disease Control and Prevention, and Researcher Wu Guizhen, Director of the BSL-3 Laboratory of the Institute of Viral Disease Control and Prevention, as co-corresponding authors, published a paper entitled: Protective prototype-Beta and Delta- Research paper on Omicron chimeric RBD-dimer vaccines against SARS-CoV-2
    .

    The research team has developed a method for designing a chimeric receptor-binding domain (RBD) dimer protein vaccine that can rapidly adapt to epidemic variants of COVID-19.
    In contrast, chimeric RBD dimers can stimulate a broader spectrum of antibody responses and provide better protection in animals
    .

    Mice and rhesus monkeys immunized with the prototype-Beta chimeric RBD dimer protein vaccine designed by this strategy showed protective effects against multiple mutant strains in challenge experiments.
    The designed Delta-Omicron chimeric RBD dimerization The in vivo vaccine efficiently protects mice against Delta and Omicron infection and the resulting pneumonia
    .

    The spike (S) protein on the surface of the new coronavirus is responsible for the receptor recognition and membrane fusion of the virus.
    The RBD on the S protein is an important vaccine target, which stimulates the production of neutralizing antibodies and has the advantage of immunofocusing
    .

    In the early stage, the team of Academician Gao Fu proposed the RBD dimer vaccine design concept of βcoronavirus S protein, and found that the neutralizing antibody titer of the immunized mouse serum with a dimer antigen designed by tandemly repeating the new coronavirus RBD was higher than that of the monomer.
    immune effect (Dai et al, 2020, Cell)
    .

    Based on this concept, the Institute of Microbiology, Chinese Academy of Sciences and Zhifei Biotechnology jointly developed the new coronary pneumonia recombinant protein vaccine ZF2001, which showed good safety and immunogenicity in Phase I/II clinical trials (Yang et al, 2021, Lancet Infectious Diseases), the results of Phase III clinical trials showed that after three doses of ZF2001 inoculation, the protective efficacy of the vaccine against new coronary pneumonia of any severity in people aged 18 and over was 81.
    43%, of which the protective efficacy for severe and above cases was 92.
    87% %
    .

    The vaccine was approved for emergency use in China and Uzbekistan in March 2021.
    It is the first recombinant protein vaccine approved for use in the world.
    It was also approved for emergency use in Indonesia and Colombia.
    In addition, ZF2001 was approved in China this year.
    Approved for marketing with conditions and as a sequential booster shot of the new crown inactivated vaccine
    .

    Recombinant subunit protein vaccines have the advantages of high yield, high safety, easy storage and transportation, and are one of the important options for the prevention of new coronary pneumonia
    .

    At present, the situation of the new crown pneumonia epidemic is still severe globally.
    New coronavirus variants are constantly emerging and popular, some of which will escape the antibody immune response of existing vaccines and cause breakthrough infections
    .

    In particular, the Delta and Omicron variants swept the world in turn and became dominant epidemic strains, posing severe challenges to epidemic prevention and control
    .

    Therefore, it is critical to develop a vaccine with broad-spectrum protection against mutants including Omicron
    .

    Based on the design basis of the prototype strain homologous RBD dimer protein vaccine (ZF2001), the researchers developed a heterologous RBD dimer protein vaccine design method that can quickly adapt to the epidemic variant of the new crown.
    The prototype-Beta chimeric protein vaccine has been verified in mice to induce a broader spectrum of antibody responses and protective effects than the homologous RBD dimers of prototype and Beta, and the prototype-Beta chimeric protein vaccine can immunize rhesus monkeys.
    Provides protection against multiple strains of COVID-19
    .

    Afterwards, the researchers designed a Delta-Omicron chimeric protein vaccine.
    Compared with the prototype homologous RBD dimer vaccine, the immunized mice stimulated a broader spectrum of antibody responses, and challenged both Delta and Omicron variants.
    Demonstrating better protective effect, these research data support the development of multivalent vaccines adapted to mutant strains to prevent circulating mutant strains.
    This study provides great support for epidemic prevention and control in the context of the current epidemic of Omicron mutant strains
    .

    Gao Fu, Academician of Beijing Institute of Biological Sciences and Institute of Microbiology, Chinese Academy of Sciences, Professor Wang Peiyi, Director of Cryo-EM Center, Southern University of Science and Technology, Researcher Dai Lianpan, Institute of Microbiology, Chinese Academy of Sciences, Researcher Peng Xiaozhong, Institute of Medical Biology, Chinese Academy of Medical Sciences, and Chief Biosafety Expert of Chinese Center for Disease Control and Prevention and Researcher Wu Guizhen, director of the BSL-3 Laboratory of the Institute for Viral Disease Control and Prevention, is the co-corresponding author
    .

    Xu Kun, assistant researcher of Beijing Institute of Biological Sciences, Chinese Academy of Sciences, Gao Ping, doctoral student of Institute of Microbiology, Chinese Academy of Sciences, Liu Sheng, postdoctoral fellow of Cryo-EM Center, Southern University of Science and Technology, Professor Lu Shuaiyao, Institute of Medical Biology, Chinese Academy of Medical Sciences, Chinese Center for Disease Control and Prevention Lei Wenwen, an associate researcher at the Institute of Control, and Zheng Tianyi, a doctoral student at the School of Basic Medicine of Zhejiang University, are the co-first authors of the paper
    .

     Paper link: https:// References: 1.
    Dai, L.
    , Zheng, T.
    , Xu, K.
    , Han, Y.
    , Xu, L.
    , Huang, E.
    , An, Y.
    , Cheng, Y.
    , Li, S.
    , Liu, M.
    , et al.
    (2020).
    A universal design of betacoronavirus vaccines against COVID-19, MERS , and SARS.
    Cell 182, 722-733 e711.
    2.
    Yang, S.
    , Li, Y.
    , Dai, L.
    , Wang, J.
    , He, P.
    , Li, C.
    , Fang, X.
    , Wang , C.
    , Zhao, X.
    , Huang, E.
    , et al.
    (2021).
    Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials.
    Lancet Infect Dis 21, 1107-1119.
    Open to reprint and welcome to forward to Moments and WeChat groups 
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.